Skip to main content
placeholder image

An analysis of metabotropic glutamate receptors 2/3 and 5 in schizophrenia, major depression and bipolar disorder from the stanley neuropathology consortium

Conference Paper


Abstract


  • Purpose: Metabotropic glutamate receptors (mGluRs) are proposed

    novel therapeutic targets for a variety of brain disorders such as

    schizophrenia (SZ), bipolar disorder (BP) and major depression (MD).

    Despite their potential, the involvement of these receptors in these

    pathological processes is uncertain. This information is crucial to

    understand the efficiency of drugs that target these receptors. Methods:

    Using post-mortem human brains, mGluR2/3 and mGluR5 binding

    densities were measured in the anterior cingulate cortex of SZ, BP, MD

    and matched controls (CT) (n=15/group) by receptor autoradiography.

    Results: Whilst preliminary analyses indicated no diagnostic effect in

    mGluR2/3 or mGluR5 binding densities, mGluR2/3 binding negatively

    correlated with age at death in the CT (r=-0.695, p=0.004) and SZ (r=-

    0.528, p=0.043) groups, but not MD or BP. Contrarily, mGluR5 displayed

    a borderline positive correlation with age at death in SZ (r=0.505,

    p=0.055) and MD (r=-0.453, p=0.090) subjects. Furthermore, mGluR2/3

    and mGluR5 binding correlated in subjects with SZ (r=-0.516, p=0.049),

    but not BP, MD or CT groups. Conclusion: Targeting mGluRs may

    provide a therapeutic mechanism to modulate glutamatergic activity in

    psychiatric disorders. Our findings of unaltered levels of mGluRs in SZ,

    BD, and MD may be beneficial by potentially providing an unhindered

    therapeutic target. However the association between age and both

    mGluR2/3 and mGluR5 binding in SZ subjects may have age-dependant

    therapeutic implications for the use of these drugs in SZ patients. There

    are no published investigations examining mGluR function, which may

    be integral to interpreting absence of change in mGluR protein levels.

Publication Date


  • 2013

Citation


  • Matosin, N., Frank, E., Fernandez, F., Deng, C., Wong, J., Huang, X. F. & Newell, K. A. (2013). An analysis of metabotropic glutamate receptors 2/3 and 5 in schizophrenia, major depression and bipolar disorder from the stanley neuropathology consortium. 33rd Meeting of the Australian Neuroscience Society: Program, Abstracts & List of Registrants (pp. 49-49). Australia: ANS.

Ro Metadata Url


  • http://ro.uow.edu.au/smhpapers/898

Start Page


  • 49

End Page


  • 49

Place Of Publication


  • Australia

Abstract


  • Purpose: Metabotropic glutamate receptors (mGluRs) are proposed

    novel therapeutic targets for a variety of brain disorders such as

    schizophrenia (SZ), bipolar disorder (BP) and major depression (MD).

    Despite their potential, the involvement of these receptors in these

    pathological processes is uncertain. This information is crucial to

    understand the efficiency of drugs that target these receptors. Methods:

    Using post-mortem human brains, mGluR2/3 and mGluR5 binding

    densities were measured in the anterior cingulate cortex of SZ, BP, MD

    and matched controls (CT) (n=15/group) by receptor autoradiography.

    Results: Whilst preliminary analyses indicated no diagnostic effect in

    mGluR2/3 or mGluR5 binding densities, mGluR2/3 binding negatively

    correlated with age at death in the CT (r=-0.695, p=0.004) and SZ (r=-

    0.528, p=0.043) groups, but not MD or BP. Contrarily, mGluR5 displayed

    a borderline positive correlation with age at death in SZ (r=0.505,

    p=0.055) and MD (r=-0.453, p=0.090) subjects. Furthermore, mGluR2/3

    and mGluR5 binding correlated in subjects with SZ (r=-0.516, p=0.049),

    but not BP, MD or CT groups. Conclusion: Targeting mGluRs may

    provide a therapeutic mechanism to modulate glutamatergic activity in

    psychiatric disorders. Our findings of unaltered levels of mGluRs in SZ,

    BD, and MD may be beneficial by potentially providing an unhindered

    therapeutic target. However the association between age and both

    mGluR2/3 and mGluR5 binding in SZ subjects may have age-dependant

    therapeutic implications for the use of these drugs in SZ patients. There

    are no published investigations examining mGluR function, which may

    be integral to interpreting absence of change in mGluR protein levels.

Publication Date


  • 2013

Citation


  • Matosin, N., Frank, E., Fernandez, F., Deng, C., Wong, J., Huang, X. F. & Newell, K. A. (2013). An analysis of metabotropic glutamate receptors 2/3 and 5 in schizophrenia, major depression and bipolar disorder from the stanley neuropathology consortium. 33rd Meeting of the Australian Neuroscience Society: Program, Abstracts & List of Registrants (pp. 49-49). Australia: ANS.

Ro Metadata Url


  • http://ro.uow.edu.au/smhpapers/898

Start Page


  • 49

End Page


  • 49

Place Of Publication


  • Australia